<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171228038115N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-05-25</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of therapeutic outcomes and complications of Overnight stay versus ordinary admission (3 days) after Percutaneous Nephrolithotomy</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of therapeutic outcomes and complications of Overnight stay after  Percutaneous Nephrolithotomy versus ordinary admission (3 days) in patients with renal stones: a randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2013-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>300</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/28636</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Using block randomization method, the patients will be categorized into two groups. Each block contains 4 components named "A" and "B" representing two methods of interest. Based on the permutation of the words (A and B), six blocks are defined:
1: AABB
2: BBAA
3: ABBA
4: BAAB
5: ABAB
6: BABA.
We will use numbers 1 to 6 from  random numbers table to choose a block randomly. Numbers 0, 7, 8, and 9 will be  ignored, Blinding description: The participant has no information about the time of discharge.</study_design>
      <phase>2</phase>
      <hc_freetext>Stone Kidney.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In patients receiving general or spinal anesthesia, 5-French Ureteral Stent was placed on the affected side through cystoscopy. Then in dorsal lumbotomy position or supine position, pyelocaliceal system and stones were determined by contrast and fluoroscopy or ultrasonography, and a Chiba needle was passed into the selected calyces of the kidney. A guidewire was passed through the needle into the pelvis. Over the guidewire the dilatators and then working element (26-30F) were placed, and by using normal saline solution as irrigating solution, 24 French nephroscope was passed inside Amplatz sheaths and the stone(s) were crushed by pneumatic lithotripsy and removed with grasper. Finally, a nephrostomy tube was fixed in the kidney. The size of the nephrostomy tube was 20-24F depending on bleeding during the procedure,extent of manipulation, and surgeon’s preferences. If a considerable amount of the stone residue (&gt;5mm) was observed on control fluoroscopy at the end of the procedure, the patient was excluded from the study. All the procedures were carried out by a surgeon.In group was discharged after extracting Foley catheter, ureter stent, and nephrostomy tub. Intervention 2: Control group: In patients receiving general or spinal anesthesia, 5-French Ureteral Stent was placed on the affected side through cystoscopy. Then in dorsal lumbotomy position or supine position, pyelocaliceal system and stones were determined by contrast and fluoroscopy or ultrasonography, and a Chiba needle was passed into the selected calyces of the kidney. A guidewire was passed through the needle into the pelvis. Over the guidewire. The dilatators and then working element (26-30F) were placed, and by using normal saline solution as irrigating solution, 24 French nephroscope was passed inside Amplatz sheaths and the stone(s) were crushed by pneumatic lithotripsy and removed with grasper. Finally, a nephrostomy tube was fixed in the kidney. The size of the nephrostomy tube was 20-24F depending on bleeding during the procedure, extent of manipulation, and surgeon’s preferences. If a considerable amount of the stone residue (&gt;5mm) was observed on control fluoroscopy at the end of the procedure, the patient was excluded. The nephrostomy tube was removed on the second postoperative day. The patient was discharged on the third postoperative day after removing the Foley and the ureteral sten. Nephrostomy tube was extracted the day after surgery and the patient was discharged on the third postoperative day after extracting Foley catheter and ureter stent.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Needs to review</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hormoz Karami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>9th Boostan, Pasdaran St, Tehran Province</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1983969411</zip>
        <telephone>+98 21 2254 9039</telephone>
        <email>r.bandari2314@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hormoz Karami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>9th Boostan, Pasdaran St, Tehran city</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1983969411</zip>
        <telephone>+98 21 2254 9039</telephone>
        <email>r.bandari2314@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Acceptable anesthesia risk (ASA class&lt; 3)
No Single kidney or renal insufficiency
No Pyonephrosis or infected stone
Insignificant residual stone (&lt;5mm)
No intra or postoperative complications
≤ 1 unit blood transfusion during operation
&lt; 3 units hemoglobin decrease in the next morning</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Taking anti-coagulants
UTI
High creatinine</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In patients receiving general or spinal anesthesia, 5-French Ureteral Stent was placed on the affected side through cystoscopy. Then in dorsal lumbotomy position or supine position, pyelocaliceal system and stones were determined by contrast and fluoroscopy or ultrasonography, and a Chiba needle was passed into the selected calyces of the kidney. A guidewire was passed through the needle into the pelvis. Over the guidewire the dilatators and then working element (26-30F) were placed, and by using normal saline solution as irrigating solution, 24 French nephroscope was passed inside Amplatz sheaths and the stone(s) were crushed by pneumatic lithotripsy and removed with grasper. Finally, a nephrostomy tube was fixed in the kidney. The size of the nephrostomy tube was 20-24F depending on bleeding during the procedure,extent of manipulation, and surgeon’s preferences. If a considerable amount of the stone residue (&gt;5mm) was observed on control fluoroscopy at the end of the procedure, the patient was excluded from the study. All the procedures were carried out by a surgeon.In group was discharged after extracting Foley catheter, ureter stent, and nephrostomy tub</i_keyword>
      <i_keyword>Control group: In patients receiving general or spinal anesthesia, 5-French Ureteral Stent was placed on the affected side through cystoscopy. Then in dorsal lumbotomy position or supine position, pyelocaliceal system and stones were determined by contrast and fluoroscopy or ultrasonography, and a Chiba needle was passed into the selected calyces of the kidney. A guidewire was passed through the needle into the pelvis. Over the guidewire. The dilatators and then working element (26-30F) were placed, and by using normal saline solution as irrigating solution, 24 French nephroscope was passed inside Amplatz sheaths and the stone(s) were crushed by pneumatic lithotripsy and removed with grasper. Finally, a nephrostomy tube was fixed in the kidney. The size of the nephrostomy tube was 20-24F depending on bleeding during the procedure, extent of manipulation, and surgeon’s preferences. If a considerable amount of the stone residue (&gt;5mm) was observed on control fluoroscopy at the end of the procedure, the patient was excluded. The nephrostomy tube was removed on the second postoperative day. The patient was discharged on the third postoperative day after removing the Foley and the ureteral sten. Nephrostomy tube was extracted the day after surgery and the patient was discharged on the third postoperative day after extracting Foley catheter and ureter stent.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Hemoglobin change. Timepoint: 1-3 days. Method of measurement: Blood test.</prim_outcome>
      <prim_outcome>Creatinine change. Timepoint: 1-3 days. Method of measurement: Blood test.</prim_outcome>
      <prim_outcome>Patients' non complicated discharge after one day. Timepoint: 1day. Method of measurement: Kidney, ureters and bladder x-ray (KUB), renal ultrasonography, checke hemoglobin (Hb) and creatinine (Cr), sodium and potassium .</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Fever. Timepoint: first 24 hour. Method of measurement: thermometer.</sec_outcome>
      <sec_outcome>Residual stone. Timepoint: first 24 hour. Method of measurement: Sonography.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2013-03-12</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>9th Boostan ,Pasdaran St,Tehran. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
